Lazard Asset Management LLC Cuts Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Lazard Asset Management LLC lessened its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 84.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,432 shares of the company’s stock after selling 118,869 shares during the quarter. Lazard Asset Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $1,032,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth $31,000. KBC Group NV purchased a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth $34,000. Smartleaf Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at about $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at about $41,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on KNSA shares. JPMorgan Chase & Co. raised their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, July 29th. Jefferies Financial Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Wedbush raised their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.38.

Kiniksa Pharmaceuticals International Stock Up 2.8%

Shares of KNSA opened at $78.08 on Thursday. Kiniksa Pharmaceuticals International, plc has a 52-week low of $31.78 and a 52-week high of $82.94. The stock has a fifty day simple moving average of $60.43 and a two-hundred day simple moving average of $51.98. The company has a market capitalization of $6.01 billion, a PE ratio of 80.49 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The firm had revenue of $243.60 million for the quarter, compared to analysts’ expectations of $226.49 million. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 51.98% of the stock is owned by company insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.